Given that HPK1 inhibition was shown to enhance antitumor immunity [207], Yang et al. explored whether an HPK1 inhibitor could act synergistically with anti-PD-1 immunotherapy for B-cell NHL in terms of tumor response, as well as its effect on NLRP3 expression. This evidence concerns the gene PDCD1 and B-cell non-Hodgkin lymphoma.